The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 2, 2002, Pages 401-405

  Calvente, Patricia R V ^a   Araujo, Carlos C S ^a   Bergamo, Marcelo ^a   Abilio, Vanessa C ^a   D'Almeida, Vânia ^b   Ribeiro, Rosana De A ^a   Frussa Filho, Roberto ^a  

^a Departamento De Farmacologia   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

3 nitropropionic acid; Rat; Reserpine; Tardive dyskinesia; Tongue protrusion

Indexed keywords

3 NITROPROPIONIC ACID; RESERPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MOVEMENT; CONTROLLED STUDY; DRUG EFFECT; IMMOBILIZATION; LOCOMOTION; MALE; NEUROTOXICITY; NONHUMAN; RAT; TARDIVE DYSKINESIA; TONGUE;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CONVULSANTS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DYSKINESIA, DRUG-INDUCED; MALE; MITOCHONDRIA; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, WISTAR; RESERPINE;

EID: 0036137889     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00255-X     Document Type: Article

References (34)

1. The mitochondrial toxin 3-nitropropionic acid induces vacuous chewing movements in rats. Implications for tardive dyskinesia?
2. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats
3. Oral dyskinesia and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid
4. 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice
5. Haloperidol-induced cell death-mechanism and protection with vitamin E in vitro
6. Oxidative stress-resistant cells are protected against haloperidol toxicity
7. Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system
8. Effects of age on a new animal model of tardive dyskinesia
9. Tardive dyskinesia - Pathophysiology
10. Ascorbic acid and α-tocopherol attenuate methylmalonic acid-induced convulsions
11. Effects of single and long-term of metoclopramide administration on open-field and stereotyped behavior in rats
12. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication
13. Tardive dyskinesia: Prevalence, incidence and risk factors
14. Haloperidol increases spreading and nitric oxide production in macrophages from tumor-bearing mice: A possible mechanism for its antitumoral effect
15. Neuroleptic-induced oral movements in rats: Methodological issues
16. Oxygen free radicals and neuropsychiatric illness
17. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia
18. Reduction of myocardial ischemic reperfusion injury by sialylated glycosphingolipids gangliosides
19. Buspirone in the treatment of tardive dyskinesia
20. Tardive dyskinesia: A review and current treatment options
21. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment
22. Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats
23. Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: Support for a model of tardive dyskinesia
24. Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia
25. Effects of buspirone on an animal model of tardive dyskinesia
26. Reserpine does not induce orofacial dyskinesia in spontaneously hypertensive rats
27. Acute reserpine administration elicits long-term spontaneous oral dyskinesia
28. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazide, reserpine and electroconvulsive therapy
29. Effects of monosialoganglioside on a new model of tardive dyskinesia
30. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: Phenomenology, pathophysiology and putative relationship to tardive dyskinesia
31. Rodent and other animal models of tardive dyskinesia during long-term neuroleptic drug administration: Controversies and implications for the clinical syndrome
32. Mitochondrial diseases in man and mouse
33. Can supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia?